37,208 Shares in Elanco Animal Health Incorporated $ELAN Bought by Securian Asset Management Inc.

Securian Asset Management Inc. bought a new stake in Elanco Animal Health Incorporated (NYSE:ELAN) during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 37,208 shares of the company’s stock, valued at approximately $749,000.

Several other hedge funds and other institutional investors also recently modified their holdings of ELAN. Jennison Associates LLC increased its holdings in shares of Elanco Animal Health by 322.0% in the 2nd quarter. Jennison Associates LLC now owns 3,234,717 shares of the company’s stock worth $46,192,000 after acquiring an additional 2,468,122 shares during the period. Goldman Sachs Group Inc. grew its position in Elanco Animal Health by 104.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company’s stock worth $50,268,000 after purchasing an additional 2,445,872 shares during the last quarter. Primecap Management Co. CA grew its position in Elanco Animal Health by 3.1% in the 2nd quarter. Primecap Management Co. CA now owns 51,766,814 shares of the company’s stock worth $739,230,000 after purchasing an additional 1,543,279 shares during the last quarter. Norges Bank acquired a new stake in shares of Elanco Animal Health in the second quarter valued at approximately $12,502,000. Finally, Brandes Investment Partners LP raised its holdings in shares of Elanco Animal Health by 11.3% during the second quarter. Brandes Investment Partners LP now owns 8,100,322 shares of the company’s stock valued at $115,673,000 after buying an additional 820,901 shares during the last quarter. Institutional investors and hedge funds own 97.48% of the company’s stock.

Analysts Set New Price Targets

ELAN has been the subject of a number of recent analyst reports. Stifel Nicolaus increased their price objective on Elanco Animal Health from $18.00 to $23.00 and gave the stock a “buy” rating in a report on Wednesday, September 24th. Wall Street Zen cut Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research note on Sunday. JPMorgan Chase & Co. raised Elanco Animal Health from a “neutral” rating to an “overweight” rating and raised their price target for the company from $18.00 to $24.00 in a report on Tuesday, October 7th. Barclays started coverage on shares of Elanco Animal Health in a report on Tuesday, December 9th. They issued an “overweight” rating and a $30.00 price objective for the company. Finally, Argus raised shares of Elanco Animal Health from a “hold” rating to a “buy” rating and set a $25.00 target price on the stock in a research note on Wednesday, November 19th. Two analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $23.78.

Insider Buying and Selling at Elanco Animal Health

In related news, CFO Robert M. Vanhimbergen acquired 6,950 shares of the business’s stock in a transaction dated Thursday, December 11th. The stock was bought at an average price of $21.64 per share, for a total transaction of $150,398.00. Following the transaction, the chief financial officer owned 124,233 shares of the company’s stock, valued at approximately $2,688,402.12. The trade was a 5.93% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Lawrence Erik Kurzius acquired 10,000 shares of Elanco Animal Health stock in a transaction dated Friday, December 12th. The shares were bought at an average cost of $21.30 per share, with a total value of $213,000.00. Following the completion of the purchase, the director owned 131,773 shares in the company, valued at approximately $2,806,764.90. This represents a 8.21% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders acquired 43,450 shares of company stock valued at $937,883 in the last ninety days. Company insiders own 0.89% of the company’s stock.

Elanco Animal Health Trading Up 1.0%

Shares of ELAN stock opened at $23.47 on Friday. The stock has a 50-day simple moving average of $22.27 and a 200 day simple moving average of $19.32. Elanco Animal Health Incorporated has a fifty-two week low of $8.02 and a fifty-two week high of $23.89. The stock has a market capitalization of $11.66 billion, a P/E ratio of 391.20, a P/E/G ratio of 3.26 and a beta of 1.87. The company has a quick ratio of 1.23, a current ratio of 2.40 and a debt-to-equity ratio of 0.59.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings results on Wednesday, November 5th. The company reported $0.19 EPS for the quarter, topping the consensus estimate of $0.13 by $0.06. Elanco Animal Health had a net margin of 0.78% and a return on equity of 7.41%. The firm had revenue of $1.14 billion for the quarter, compared to analysts’ expectations of $1.09 billion. During the same period in the previous year, the business earned $0.13 earnings per share. Elanco Animal Health’s revenue for the quarter was up 10.4% compared to the same quarter last year. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS and its Q4 2025 guidance at 0.090-0.120 EPS. On average, sell-side analysts expect that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.